Key facts
- This page summarizes Robert Dickey IV's Form 5 filing for AngioGenex, Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 16 Feb 2022, 12:49.
Robert Dickey IV - 31 Dec 2021 Form 5 Insider Report for AngioGenex, Inc.
- Reporting relationship
- Director, INDEPENDENT DIRECTOR
- Issuer ticker
- N/A
- Reported as of
- 31 Dec 2021
- Net transaction value
- +$32,500
- SEC form
- 5
- Accepted by SEC
- 16 Feb 2022, 12:49:31 UTC
- Next SEC filing
- 04 Apr 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ ROBERT DICKEY IV
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Robert Dickey IV filed Form 5 for AngioGenex, Inc. on 16 Feb 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: +$32,500.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 5 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AGGX
transaction
Derivative
Stock Option
Award
- Transaction value
- $32,500
- Shares
- +250,000
- Change %
- +42%
- Price
- $0.1300*
- Shares after
- 850,000
- Date
- 02 Sep 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 250,000
- Exercise price
- $0.1300
* marks a reported price that did not pass the local price check.